Results 41 to 50 of about 309,486 (308)

Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. [PDF]

, 2017
Background and Aims: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States and recurrent HCV following liver transplantation is a major cause of allograft loss and mortality.
Aby, Elizabeth, Agopian, Vatche, Busuttil, Ronald W, French, Samuel W, Grotts, Jonathan F, Jimenez, Melissa A, Saab, Sammy   +6 more
core   +1 more source

Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients

Antiviral Therapy, 2022
Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant.
Aude Boignard, Caroline Augier, Mathilde Kheng, Olivier Epaulard, Raphaele Germi   +4 more
doaj   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

Advances in Antiviral Therapy.

Journal of Investigative Dermatology, 1984
Recent developments have increased the options for treatment of viral infections. Vidarabine, an agent originally released for herpes simplex encephalitis, has more recently been shown to be of benefit in neonatal herpes simplex infection and in varicella-zoster infections in immunocompromised hosts.
openaire   +2 more sources

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. [PDF]

, 2017
Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Bau, Sherona N, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco A, El-Kabany, Mohammed M, Esmailzadeh, Negin L, Fong, Tiffany M, Grotts, Jonathan, Han, Steven-Huy B, Jimenez, Melissa A, Kachadoorian, Caterina A, Kang, Susan, Mai, Michelle H, Ramirez, Samantha D, Rheem, Justin, Saab, Sammy   +15 more
core   +1 more source

Reciprocal control of viral infection and phosphoinositide dynamics

FEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source

Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. [PDF]

, 2016
HCV is the leading cause of death from liver disease and is the most common indication for a liver transplantation. Although HCV is a widespread health problem, disease management is particularly challenging in several key subpopulations, including liver
Burra, Patrizia, Russo, Francesco Paolo, Zanetto, A   +2 more
core   +1 more source

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections

Pharmaceutics
Over 80% of the world’s deadliest pandemics are caused by viral infections, and vaccination remains the most effective way to prevent these infections from spreading. Since the discovery of the first vaccine over two centuries ago, several vaccine design
Njabulo Mnyandu, Ridhwaanah Jacobs, Patrick Arbuthnot, Mohube Betty Maepa   +3 more
doaj   +1 more source

Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review

Antiviral Therapy, 2023
Background:  Biktarvy is approved for use in HIV-1 infection in both treatment-naïve and treatment-experienced individuals, after a series of successful phase III trials.
Ellen Peters, and Collins Iwuji
doaj   +1 more source